If your legs never change no matter what you do, lipedema and inflammation are probably why

If you have spent years eating carefully, training consistently, and watching the rest of your body respond while your legs and arms remain entirely unchanged, you are not imagining it. You are not failing. And you are almost certainly not alone in having been told, at some point, that you simply need to try harder.

Lipedema is a chronic, progressive disorder of subcutaneous adipose tissue that affects an estimated 11 to 19% of women worldwide, a prevalence that most researchers consider significantly underestimated due to how frequently it is misdiagnosed or missed entirely (Tomada, Endocrines, 2025). It presents as a symmetrical, disproportionate accumulation of painful fat that affects the lower body and often the arms, spares the hands and feet, and is characterised by easy bruising, tenderness on palpation, and a sensation of heaviness that worsens through the day. It is not obesity. It does not respond to caloric restriction in the way obesity does. And understanding why requires understanding what is actually happening in the tissue.

Why lipedema fat behaves differently

Lipedema is driven by a complex interaction of genetic susceptibility and hormonal signalling, and it typically emerges or worsens during periods of significant hormonal change: puberty, pregnancy, menopause, and in some cases with oral contraceptive use. This hormonal fingerprint is not coincidental. It reflects the central role that estrogen plays in the pathophysiology of the condition.

Estrogen regulates where the female body stores fat. Specifically, it promotes accumulation of subcutaneous adipose tissue in the gluteofemoral region: the hips, thighs, and buttocks. This is the region most commonly affected by lipedema, and the mechanism involves a dysregulation of estrogen receptor expression in the adipose tissue of these areas. Research identifies a shift in the ratio of estrogen receptor alpha (ERα) to estrogen receptor beta (ERβ) in lipedema-affected fat, with consequences that ripple through the tissue's entire metabolic behaviour (Katzer et al., International Journal of Molecular Sciences, 2021).

ERα promotes healthy subcutaneous fat expansion, enhances insulin sensitivity, and supports extracellular matrix integrity. ERβ has the opposite effect: it promotes inflammation, fibrosis, and impaired lipolysis. In lipedema, ERβ dominates in the affected regions, creating a tissue environment that resists normal fat mobilisation and drives the structural changes women can feel and see (Pinto da Costa Viana, Caseri Câmara and Borges Palau, International Journal of Molecular Sciences, 2025).

This receptor imbalance also explains why lipedema fat is resistant to caloric restriction. When you eat less, your body draws on fat stores through lipolysis. But in lipedema tissue, the signalling pathways that enable lipolysis are suppressed. The fat in your legs does not respond to the same metabolic cues as the fat elsewhere in your body. This is a structural, hormonal reality, not a behavioural one.

The picture becomes more complex when you consider that lipedema adipose tissue also produces estrogen locally, through the activity of aromatase (CYP19A1) and the enzyme 17β-HSD1, which converts the weaker estrone into active estradiol. Research shows that 17β-HSD1 expression is increased approximately twofold in lipedema adipocytes, sustaining a locally hyperestrogenic microenvironment even when systemic estradiol levels are low, as in postmenopause (Szél et al., Medical Hypotheses, 2014). This intracrine cycle perpetuates adipogenesis, inflammation, and fibrosis within the tissue regardless of what is happening hormonally at the systemic level.

What perimenopause and menopause do to lipedema

For women with lipedema, the menopausal transition is frequently a turning point. Approximately 67% of women with lipedema report significant symptom exacerbation at the onset of menopause, and around 20% of cases are first diagnosed during this period (Tomada, Endocrines, 2025).

The mechanism is specific. As systemic estradiol declines, ERα expression in adipose tissue falls and ERβ rises compensatorily. For women without lipedema, this shift contributes to the well-documented changes in fat distribution during menopause: a move from gynoid (lower body) to android (central) fat accumulation. For women with lipedema, whose ERα/ERβ balance is already dysregulated in the affected tissue, this shift amplifies an existing dysfunction. The anti-inflammatory, anti-adipogenic effects of ERα are further suppressed; the pro-inflammatory, pro-fibrotic effects of ERβ are further enhanced (Pinto da Costa Viana, Caseri Câmara and Borges Palau, International Journal of Molecular Sciences, 2025).

Simultaneously, the decline in progesterone during the menopausal transition reduces the activity of 17β-HSD2, the enzyme responsible for converting active estradiol back into inactive estrone. This progesterone resistance allows active estradiol to persist in the tissue for longer, intensifying estrogenic signalling through ERβ and sustaining the inflammatory, fibrotic environment that characterises advanced lipedema.

The result is that menopause does not simply worsen existing lipedema through the same mechanisms. It introduces additional hormonal disruption that compounds what is already there, often producing a more treatment-resistant clinical presentation than a woman experienced during her reproductive years.

A more precise way to understand disease progression

One of the significant frustrations women with lipedema describe is feeling caught between the established staging classifications: not quite fitting Stage 1, but not yet Stage 2. That experience has a clinical basis.

Research published in 2025 proposed the addition of intermediate stages 1.5 and 2.5 to the existing classification system, based on physical examination data from 102 women across a specialised lipedema clinic. The rationale is that disease progression occurs along a continuum rather than in discrete jumps, and that the tissue changes between stages are often clinically meaningful (Al-Ghadban et al., Life, 2025).

Stage 1.5 captures the transition between smooth skin (Stage 1) and the uniform skin indentations of Stage 2, characterised by indentations affecting only the upper or lower half of the thigh rather than its full extent. Stage 2.5 marks the beginning of lobule formation, particularly at the hips and knees, before the extensive deformations of Stage 3. Both intermediate stages carry clinical weight: 90% of women with Stage 1.5 lipedema report pain, and 100% of women with Stage 2.5 report it, figures that exceed the pain prevalence at both the adjacent full stages and reinforce that these are genuinely distinct presentations (Al-Ghadban et al., Life, 2025).

The same research confirmed that fat covering the shin is an early and consistent marker of lipedema across all stages, present at Stage 1 and remaining elevated throughout later stages with no significant variation between them. The ankle cuff, by contrast, is a later finding, becoming significant only from Stage 2.5 onward. This distinction matters for early identification and for women who are trying to understand what they are observing in their own bodies.

The systemic picture: fatigue, brain fog, and cold skin

Lipedema is still not widely classified as a systemic disease in clinical guidelines, despite accumulating evidence that its effects extend well beyond the affected tissue. The 2025 staging research found that 87% of participants reported extreme fatigue and 76% reported brain fog: persistent cognitive impairment characterised by difficulty concentrating, reduced multitasking capacity, and impaired memory (Al-Ghadban et al., Life, 2025).

These are not secondary symptoms of frustration or distress, though psychological burden is real and significant. Research on lipedema tissue has identified mitochondrial dysfunction and altered oxidative phosphorylation as features of the condition at the molecular level, and mitochondrial complex dysfunction is associated with the kind of cognitive impairment described as brain fog in other inflammatory conditions including long COVID (Al-Ghadban et al., Life, 2025). The mechanism is plausible and the clinical picture consistent.

Peripheral hypothermia, or skin that feels cold to touch in affected areas, is another measurable systemic finding. Qualitative thermography across the 2025 cohort showed that hypothermia in both legs and arms was significantly more prevalent from Stage 1.5 onward compared to Stage 1, reflecting the increasing volume of adipose tissue and its insulating effect on circulation (Al-Ghadban et al., Life, 2025). Women often describe this as noticing that their legs feel different in temperature from the rest of their body, and that observation is clinically valid.

What nutrition can and cannot do

There is no proven dietary treatment for lipedema in the sense that no single nutritional approach has been validated in large, long-term randomised controlled trials with lipedema-specific populations. The evidence base is growing but it is still developing, and honesty about this is important (Atabilen Pınar et al., Nutrition Reviews, 2025).

What the research does consistently show is that nutrition plays a meaningful role in symptom management and in slowing disease progression, and that the primary mechanism is anti-inflammatory rather than purely calorie-related.

The ketogenic diet has the most substantial body of evidence for lipedema specifically. A 2024 randomised controlled trial found that a low-carbohydrate diet produced significantly greater weight loss and pain reduction than an isoenergetic low-fat control diet over eight weeks (Lundanes et al., Obesity, 2024). A 2024 systematic review and meta-analysis found that low-carbohydrate, high-fat diets produced significant reductions in BMI, total body weight, waist and hip circumferences, and self-reported pain sensitivity across the included studies (Amato, Amato and Benitti, Nutrients, 2024).

The mechanism behind this is important to understand. The ketogenic state inhibits the NLRP3 inflammasome, a specific inflammatory pathway strongly implicated in lipedema tissue pathology. Ketone bodies, particularly beta-hydroxybutyrate, reduce the secretion of pro-inflammatory cytokines including IL-6 and TNF-α. Carbohydrate restriction also lowers insulin concentrations sufficiently to promote lipolysis of lipedema adipocytes, addressing the anti-lipolytic environment that makes this fat so difficult to mobilise through conventional caloric restriction (Tomada, Endocrines, 2025).

The modified Mediterranean-ketogenic diet (MMKD) combines the anti-inflammatory food principles of the Mediterranean pattern with a ketogenic carbohydrate level (under 30g per day). A pilot study from Di Renzo's research group found significant reductions in body weight, waist and hip circumferences, and total fat mass after ten weeks on MMKD, alongside reductions in pain and improvements in sleep quality and fatigue, with lean mass maintained throughout (Di Renzo et al., Nutrients, 2023). This combined approach addresses both the inflammatory burden and the practical sustainability challenges of a strict ketogenic diet, and is currently the dietary model with the most clinical rationale for lipedema management.

One important caveat: when a ketogenic diet protocol interrupts and a standard diet resumes, pain levels tend to return to baseline. The anti-inflammatory benefit appears to depend on maintaining the metabolic state (Sørlie et al., Obesity Science and Practice, 2022). This is a significant practical consideration for women with lipedema when thinking about any dietary approach as a long-term strategy rather than an intervention.

Beyond diet pattern, the research points to several nutritional principles that apply regardless of which specific approach a woman follows. Avoiding glycaemic spikes is consistently emphasised: elevated insulin has pro-inflammatory effects and promotes lipogenesis and water retention. Choosing complex carbohydrates over simple ones, pairing carbohydrates with protein and healthy fats, and allowing adequate time between meals to allow insulin to return to baseline are all mechanistically sound recommendations for lipedema (Tomada, Endocrines, 2025).

Individual food intolerances require individual assessment. Gluten and lactose removal are frequently recommended in lipedema communities, and there is biological plausibility for their inflammatory role in some women through intestinal permeability mechanisms. However, the evidence does not support routine elimination for all women with lipedema. If a specific intolerance is present or suspected, elimination is reasonable. If it is not, an unnecessary elimination diet carries its own risks including nutritional deficiency and disordered eating, both of which are already elevated concerns in this population (Atabilen Pınar et al., Nutrition Reviews, 2025).

BMR calculation in lipedema also requires specific attention. Standard predictive equations (Harris-Benedict, Mifflin-St Jeor) are up to 60% inconsistent in women with lipedema because they do not account for the disproportionate fat distribution in the lower extremities. A new BMR formula developed specifically for lipedema, incorporating lean body mass, body fat mass, total body water, visceral fat level, waist, hip, WHR, height, weight, BMI, and age, has been proposed and published as a more accurate basis for caloric planning (Jeziorek et al., Metabolites, 2024). This matters practically: an inaccurate energy calculation is a poor foundation for a nutritional plan.

Nutritional supplements which ones & what the evidence supports

No dietary supplement has been proven effective for lipedema in clinical trials. This is the honest starting point, and it matters, because the supplement landscape around lipedema is crowded with claims that outrun the evidence (Atabilen Pınar et al., Nutrition Reviews, 2025).

That said, several supplements have a strong mechanistic rationale and are supported by the clinical literature as warranting consideration, with the understanding that professional supervision is essential and that deficiency assessment should precede supplementation rather than following a generic protocol.

Omega-3 fatty acids (DHA and EPA) are the most consistently supported. Their anti-inflammatory mechanism is well established: they regulate macrophage activation and reduce pro-inflammatory cytokine secretion, which is directly relevant to the inflammatory microenvironment of lipedema tissue. They also appear to modulate pain signalling through transient receptor potential channels. A daily intake of at least 1g of combined DHA and EPA is suggested in the lipedema-specific literature (Cannataro and Cione, Nutraceuticals, 2022).

Vitamin C supports both antioxidant status and collagen synthesis, the latter being directly relevant to connective tissue integrity in lipedema. One case report documented positive outcomes with 1000mg daily alongside a ketogenic dietary intervention (Cannataro et al., Life, 2021).

Vitamin B12 has a specific role in the neuropathic pain component that becomes more evident in later stages of lipedema, where nerve involvement contributes to the pain picture (Cannataro and Cione, Nutraceuticals, 2022).

Curcumin operates as both an NF-κB regulator and an Nrf2 activator, targeting two of the key inflammatory signalling pathways implicated in lipedema. A polyphenol-rich diet alongside supplementation from multiple polyphenol sources at 100 to 150mg daily is suggested in the clinical literature (Cannataro and Cione, Nutraceuticals, 2022).

Selenium deficiency has been identified in a proportion of women with lipedema in retrospective data, though the authors noted this may reflect general population deficiency rather than a lipedema-specific pattern. Plasma levels should be assessed and supplementation considered where deficiency is confirmed (Atabilen Pınar et al., Nutrition Reviews, 2025).

For women following ketogenic dietary protocols, specific micronutrient monitoring is important. Studies have shown that after three months on a ketogenic diet, manganese, vitamin D, and vitamin E requirements can become difficult to meet through food alone. Vitamin C is frequently insufficient in a strict ketogenic diet. Electrolyte balance (sodium, magnesium, potassium) requires active attention, particularly in the early adaptation phase (Atabilen Pınar et al., Nutrition Reviews, 2025).

Bariatric surgery and what it cannot do

For women with lipedema who also carry significant obesity as a comorbidity, bariatric surgery is sometimes presented as a solution. The clinical evidence is consistent on this point: bariatric surgery can meaningfully assist with overall metabolic weight and obesity-related comorbidities including insulin resistance and cardiovascular risk. It cannot reduce the localised fat accumulation or fat cell hypertrophy specific to lipedema, and it does not resolve lipedema pain (Atabilen Pınar et al., Nutrition Reviews, 2025).

Women who undergo bariatric surgery without a lipedema diagnosis often continue to experience the characteristic lower body fat distribution and pain after surgery, sometimes to their significant distress and confusion. If lipedema is diagnosed alongside obesity, surgery should only be considered when diet and exercise have not produced adequate results, BMI exceeds 40 kg/m², and the woman has been clearly informed that pain related to lipedema is likely to persist (Atabilen Pınar et al., Nutrition Reviews, 2025).

This is not a reason to dismiss the role of weight management in lipedema care. Excess weight exacerbates lipedema symptoms and accelerates progression. Managing the obesity component through evidence-based nutrition does reduce limb volume and improve quality of life. The distinction is between what weight management can achieve and what it cannot change about the underlying connective tissue disorder.

Why precision matters more than any single protocol

The consistent message across the current lipedema literature is that nutritional management in this condition is complicated by frequent comorbidities, individual variation in inflammatory burden, food tolerances, hormonal status, gut function, and metabolic state. Hashimoto's thyroiditis, PCOS, insulin resistance, and depression are all more prevalent in women with lipedema than in the general population, and each shapes how a woman responds to dietary intervention (Atabilen Pınar et al., Nutrition Reviews, 2025).

A dietary framework that works for one woman with lipedema may not work for another, and the reasons are biological rather than motivational. Standard BMR equations underestimate her energy needs. Standard anti-inflammatory eating may not address her specific inflammatory picture. Standard protein recommendations may not account for the anabolic resistance that compounds in perimenopause on top of the muscle function deficits already documented in lipedema.

For women in perimenopause, the hormonal and nutritional picture layers in ways that require genuine clinical attention. Where HRT is appropriate and initiated within the timing window, the evidence from the lipedema literature suggests that transdermal estradiol applied to unaffected areas may help restore some ERα/ERβ balance, reduce the inflammatory cascade in affected tissue, and support the metabolic and nutritional work happening alongside it (Pinto da Costa Viana, Caseri Câmara and Borges Palau, International Journal of Molecular Sciences, 2025).

The goal of nutritional therapy in lipedema is not to change the appearance of the extremities through weight loss. It is to reduce inflammation, slow progression, manage pain, and maintain the best possible metabolic health across a complex, chronic condition. That goal is achievable. It requires a precise, individualised approach built on an accurate understanding of the biology rather than on generic protocols that were never designed for this body.

If this is where you are, please work with a practitioner who understands both lipedema and the specific hormonal and nutritional complexity of perimenopause. The two are not separate conversations. Working with your GP or a specialists in this area is also reall important to get a proper diagnosis before addressing nutrition.

References:

Al-Ghadban, S., Evancio, J.V., Alfiscar, P.E.F. and Herbst, K.L. (2025) 'New characterization of lipedema stages: focus on pain, water, fat and skeletal muscle', Life, 15(9), article 1397.

Amato, A.C.M., Amato, J.L.S. and Benitti, D.A. (2024) 'The efficacy of ketogenic diets (low carbohydrate; high fat) as a potential nutritional intervention for lipedema: a systematic review and meta-analysis', Nutrients, 16(19), article 3276.

Atabilen Pınar, B., Çelik, M.N., Altıntaş Başar, H.B., Ağagündüz, D. and Karaca, O.B. (2025) 'Current evidence-based clinical nutritional approaches in lipedema: a scoping review', Nutrition Reviews, advance article. https://doi.org/10.1093/nutrit/nuaf203

Bonetti, G., Herbst, K.L., Dhuli, K., Kiani, A.K., Michelini, S., Michelini, S., Ceccarini, M.R., Michelini, S., Ricci, M., Cestari, M., Codini, M., Beccari, T., Bellinato, F., Gisondi, P. and Bertelli, M. (2022) 'Dietary supplements for lipedema', Journal of Preventive Medicine and Hygiene, 63(Suppl. 3), pp. E169–E173.

Cannataro, R. and Cione, E. (2022) 'Nutritional supplements and lipedema: scientific and rational use', Nutraceuticals, 2(4), pp. 270–277.

Cannataro, R., Michelini, S., Ricolfi, L., Caroleo, M., Gallelli, L., de Sarro, G., Onorato, A. and Cione, E. (2021) 'Management of lipedema with ketogenic diet: 22-month follow-up', Life, 11(12), article 1402.

Di Renzo, L., Gualtieri, P., Zomparelli, S., De Santis, G.L., Seraceno, S., Zuena, C., Frank, G., Cianci, R., Centofanti, D. and De Lorenzo, A. (2023) 'Modified Mediterranean-ketogenic diet and carboxytherapy as personalized therapeutic strategies in lipedema: a pilot study', Nutrients, 15(17), article 3654.

Jeziorek, M., Wronowicz, J., Janek, Ł., Kujawa, K. and Szuba, A. (2024) 'Development of new predictive equations for the resting metabolic rate (RMR) of women with lipedema', Metabolites, 14(4), article 235.

Katzer, K., Hill, J.L., McIver, K.B. and Foster, M.T. (2021) 'Lipedema and the potential role of estrogen in excessive adipose tissue accumulation', International Journal of Molecular Sciences, 22(21), article 11720.

Kruppa, P., Georgiou, I., Biermann, N., Prantl, L., Klein-Weigel, P. and Ghods, M. (2020) 'Lipedema: pathogenesis, diagnosis, and treatment options', Deutsches Ärzteblatt International, 117(22–23), pp. 396–403.

Lundanes, J., Sandnes, F., Gjeilo, K.H., Hansson, P., Salater, S., Martins, C. and Nymo, S. (2024) 'Effect of a low-carbohydrate diet on pain and quality of life in female patients with lipedema: a randomized controlled trial', Obesity, 32(6), pp. 1071–1082.

Pinto da Costa Viana, D., Caseri Câmara, L. and Borges Palau, R. (2025) 'Menopause as a critical turning point in lipedema: the estrogen receptor imbalance, intracrine estrogen, and adipose tissue dysfunction model', International Journal of Molecular Sciences, 26(15), article 7074.

Sørlie, V., De Soysa, A.K., Hyldmo, Å.A., Retterstøl, K., Martins, C. and Nymo, S. (2022) 'Effect of a ketogenic diet on pain and quality of life in patients with lipedema: the LIPODIET pilot study', Obesity Science and Practice, 8(5), pp. 483–493.

Szél, E., Kemény, L., Groma, G. and Szolnoky, G. (2014) 'Pathophysiological dilemmas of lipedema', Medical Hypotheses, 83(5), pp. 599–606.

Tomada, I. (2025) 'Lipedema: from women's hormonal changes to nutritional intervention', Endocrines, 6(2), article 24.

If you're a woman in perimenopause struggling with metabolic health despite doing "all the right things," the missing piece might be understanding your unique internal landscape. My Sérenité Women's Wellness Program uses blood pathology analysis to create truly personalized nutrition protocols that work with your specific metabolism. Learn more about working together